Literature DB >> 23637328

Clinical course, prognosis, and causes of death in mixed connective tissue disease.

Agota Hajas1, Peter Szodoray, Britt Nakken, Janos Gaal, Eva Zöld, Renata Laczik, Nora Demeter, Gabor Nagy, Zoltan Szekanecz, Margit Zeher, Gyula Szegedi, Edit Bodolay.   

Abstract

OBJECTIVE: To study the survival rate and prognostic indicators of mixed connective tissue disease (MCTD) in a Hungarian population.
METHODS: Two hundred eighty patients with MCTD diagnosed between 1979 and 2011 were followed prospectively. Clinical features, autoantibodies, and mortality data were assessed. Prognostic factors for survival were investigated and survival was calculated from the time of the diagnosis by Kaplan-Meier method.
RESULTS: A total of 22 of 280 patients died: the causes of death were pulmonary arterial hypertension (PAH) in 9 patients, thrombotic thrombocytopenic purpura in 3, infections in 3, and cardiovascular events in 7. The 5, 10, and 15-year survival rates after the diagnosis was established were 98%, 96%, and 88%, respectively. The deceased patients were younger at the diagnosis of MCTD compared to patients who survived (35.5 ± 10.4 vs 41.8 ± 10.7 yrs; p < 0.03), while there was no difference in the duration of the disease (p = 0.835). Our cohort study showed that the presence of cardiovascular events (p < 0.0001), esophageal hypomotility (p = 0.04), serositis (p < 0.001), secondary antiphospholipid syndrome (p = 0.039), and malignancy (p < 0.001) was significantly higher in the deceased patients with MCTD. The presence of anticardiolipin (p = 0.019), anti-β2-glycoprotein I (p = 0.002), and antiendothelial cell antibodies (p = 0.002) increased the risk of mortality.
CONCLUSION: Overall, PAH remained the leading cause of death in patients with MCTD. The prevalence of cardiovascular morbidity and mortality, malignancy, and thrombotic events increased during the disease course of MCTD. The presence of antiphospholipid antibodies raised the risk of mortality.

Entities:  

Keywords:  ANTIPHOSPHOLIPID SYNDROME; CARDIOVASCULAR EVENTS; CLINICAL COURSE; MIXED CONNECTIVE TISSUE DISEASE; PROGNOSIS; SURVIVAL

Mesh:

Substances:

Year:  2013        PMID: 23637328     DOI: 10.3899/jrheum.121272

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  13 in total

Review 1.  Pathophysiology and imaging of heart failure in women with autoimmune rheumatic diseases.

Authors:  Sophie I Mavrogeni; George Markousis-Mavrogenis; Loukia Koutsogeorgopoulou; Theodoros Dimitroulas; Vasiliki Vartela; Angelos Rigopoulos; Michel Noutsias; Genovefa Kolovou
Journal:  Heart Fail Rev       Date:  2019-07       Impact factor: 4.214

2.  Following leads: connecting dysphagia to mixed connective tissue disease.

Authors:  Rita de Sousa Gameiro; Ana Isabel Alves Reis; Ana Cristina Grilo; Carla Noronha
Journal:  BMJ Case Rep       Date:  2018-03-05

3.  Epidemiology of Mixed Connective Tissue Disease, 1985-2014: A Population-Based Study.

Authors:  Patompong Ungprasert; Cynthia S Crowson; Vaidehi R Chowdhary; Floranne C Ernste; Kevin G Moder; Eric L Matteson
Journal:  Arthritis Care Res (Hoboken)       Date:  2016-10-01       Impact factor: 4.794

Review 4.  Undifferentiated Connective Tissue Disease, Mixed Connective Tissue Disease, and Overlap Syndromes in Rheumatology.

Authors:  Peri Hickman Pepmueller
Journal:  Mo Med       Date:  2016 Mar-Apr

Review 5.  Microvascular damage - a marker of specific organ involvement in mixed connective tissue disease?

Authors:  Sylwia Ornowska; Marek Chojnowski; Anna Felis-Giemza; Łukasz Dudek; Marzena Olesińska
Journal:  Reumatologia       Date:  2021-04-27

6.  Capillaroscopy as a diagnostic tool in the diagnosis of mixed connective tissue disease (MCTD): a case report.

Authors:  Mislav Radić; Rebecca S Overbury
Journal:  BMC Rheumatol       Date:  2021-03-19

7.  Associations between circulating endostatin levels and vascular organ damage in systemic sclerosis and mixed connective tissue disease: an observational study.

Authors:  Silje Reiseter; Øyvind Molberg; Ragnar Gunnarsson; May Brit Lund; Trond Mogens Aalokken; Pål Aukrust; Thor Ueland; Torhild Garen; Cathrine Brunborg; Annika Michelsen; Aurelija Abraityte; Anna-Maria Hoffmann-Vold
Journal:  Arthritis Res Ther       Date:  2015-08-28       Impact factor: 5.156

8.  Disease evolution in mixed connective tissue disease: results from a long-term nationwide prospective cohort study.

Authors:  Silje Reiseter; Ragnar Gunnarsson; Jukka Corander; Joanna Haydon; May Brit Lund; Trond Mogens Aaløkken; Eli Taraldsrud; Siri Opsahl Hetlevik; Øyvind Molberg
Journal:  Arthritis Res Ther       Date:  2017-12-21       Impact factor: 5.156

Review 9.  [Mixed connective tissue disease: prevalence and clinical characteristics in African black, study of 7 cases in Gabon and review of the literature].

Authors:  Landry Missounga; Josaphat Iba Ba; Ingrid Rosalie Nseng Nseng Ondo; Maria Ines Carine Nziengui Madjinou; Doris Malekou; Emeline Gracia Mouendou Mouloungui; Emmanuel Ecke Nzengue; Jean Bruno Boguikouma; Moussavou Kombila
Journal:  Pan Afr Med J       Date:  2017-06-30

10.  Clinical and Immunological Profile of Mixed Connective Tissue Disease and a Comparison of Four Diagnostic Criteria.

Authors:  Kevin John John; Mohammad Sadiq; Tina George; Karthik Gunasekaran; Nirmal Francis; Ebenezer Rajadurai; Thambu David Sudarsanam
Journal:  Int J Rheumatol       Date:  2020-01-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.